Your resume is important to landing a job, and employers should know about all of your experience including consulting.

For mid-tier and boutique firms, competing against the larger firms offers the chance to lean into their own particular ...

Nvidia NVDA 0.89% said it has received assurances from the Trump administration that it can sell its H20 artificial-intelligence chip in China, days after Chief Executive Jensen Huang met ...

Investing.com - Nvidia (NASDAQ:NVDA), currently trading near its 52-week high with an impressive 86% revenue growth over the last twelve months, is seeking to resume sales of its H20 GPUs to China ...

The Mozambique Government has reportedly created the necessary conditions for the resumption of TotalEnergies' $20bn liquefied natural gas (LNG) project, reported Reuters, citing sources.

German automaker Volkswagen has resumed deliveries of its ID.Buzz electric minibus to the United States, a company spokesperson said on Tuesday, confirming a report by Focus magazine. The exports ...

BEIJING/HONG KONG: Nvidia said it plans to resume sales of its H20 artificial intelligence chip to China, days after its CEO, who is visiting Beijing, met U.S. President Donald Trump.

Investing.com -- The U.S. Supreme Court has cleared the way for President Donald Trump’s administration to continue dismantling the Department of Education, removing a legal obstacle that had ...

Investing.com - Goldman Sachs (NYSE: GS) has resumed coverage on CG Oncology (NASDAQ: CGON) with a Buy rating and a price target of $40.00 on Thursday. The stock, currently trading at $27.04, appears ...

Investing.com - Goldman Sachs (NYSE: GS) has resumed coverage of Halozyme Therapeutics (NASDAQ: HALO) with a Neutral rating and a $55.00 price target. The company, which has achieved a perfect ...

TG Therapeutics also discussed its financial strategy, aiming to maintain non-GAAP operating expenses at approximately $300 million for the year, excluding the cost of goods sold. The company remains ...

Investing.com - Goldman Sachs has resumed coverage of Halozyme Therapeutics (NASDAQ:HALO) with a Neutral rating and a $55.00 price target. The company, which has achieved a perfect Piotroski Score of ...